NYSE$GMED

Globus Medical Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Globus Medical's Q3 2020 performance was marked by record revenue and earnings, driven by U.S. Spine business growth and strong Adjusted EBITDA and Cash Flow.

Globus Medical reported a strong third quarter with a 10.1% increase in worldwide net sales to $216.1 million and GAAP net income rising by 15.4% to $44.2 million. Diluted EPS was $0.44, and non-GAAP diluted EPS was $0.49. The U.S. Spine business grew by 17%, offsetting a decline in Enabling Technologies revenue. The company generated $53.2 million in net cash from operating activities and $35.9 million in non-GAAP free cash flow.

  • Worldwide net sales increased by 10.1% to $216.1 million compared to Q3 2019.
  • GAAP net income rose by 15.4% to $44.2 million compared to Q3 2019.
  • Diluted EPS was $0.44, with non-GAAP diluted EPS at $0.49.
  • Non-GAAP adjusted EBITDA was 34.8% of net sales.

Headline financials

Total Revenue

$216M

Previous: $196M+10.1%
EPS (adj)

$0.49

Previous: $0.43+14.0%
Adjusted EBITDA

$34.80

Previous: $33.40+4.2%
Capital Expenditures

-$49.6M

Previous: -$55M+9.8%
Free Cash Flow

-$5.38M

Previous: -$16.7M+67.7%
Net Income

$44.2M

Previous: $38.3M+15.4%
Operating Income

$50M

Previous: $42.1M+18.9%
Gross Profit

$159M

Previous: $151M+5.4%
Cash & Equivalents

$251M

Previous: $166M+50.9%
Total Assets

$1.54B

Previous: $1.45B+6.2%
Stock-Based Comp

$7.02M

Previous: $6.9M+1.8%

Revenue & EPS history

Globus Medical · Revenue · Quarterly

$216M

Q3 2020+10.1%vs Q3 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Globus Medical · $216M total across 2 segments · Q3 2020

  • Musculoskeletal Solutions
    $207M+13.6%
  • Enabling Technologies
    $9.04M-35.0%

Forward guidance

Globus Medical withdrew full year 2020 guidance due to the continued uncertainties resulting from the COVID-19 pandemic.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.8%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.9%

Avg return

30 days after

57%

34 / 60 earnings

Positive

+36.0%

Q3 2025

Best reaction

-23.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-14.6%-10.4%
Q4 2025+4.6%+2.1%-8.8%
Q3 2025+36.0%+37.3%+47.6%
Q1 2025-23.0%-19.7%-17.3%
Q4 2024-4.6%-4.9%-12.5%
Q3 2024+10.7%+8.2%+11.2%
Q2 2024+4.0%+8.0%+4.4%
Q1 2024+22.8%+28.7%+31.6%
Q4 2023+2.2%+4.6%-3.1%
Q3 2023-1.4%-5.1%-2.5%
Q2 2023-5.0%-4.8%-9.1%
Q1 2023+2.9%-0.3%-1.8%
Q4 2022-1.2%-21.9%-29.2%
Q3 2022-4.2%+9.4%+11.5%
Q2 2022+5.4%+6.9%-2.4%
Q1 2022+0.1%+5.2%+0.1%
Q4 2021-3.1%-3.7%+1.3%
Q3 2021+0.2%-4.3%-19.4%
Q2 2021-3.3%-3.0%+1.3%
Q1 2021+3.1%+3.0%-0.9%
Q4 2020-5.7%-5.2%-10.2%
Q3 2020+2.4%+3.5%+16.9%
Q2 2020+18.5%+13.4%+13.3%
Q1 2020+8.1%+0.6%+21.4%
Q4 2019-2.1%-9.7%-29.0%
Q3 2019+3.6%+4.2%+8.2%
Q2 2019+9.9%+6.1%+12.0%
Q1 2019-1.9%-2.0%-11.0%
Q4 2018+0.2%-2.2%-0.3%
Q3 2018-8.7%-9.9%-19.4%
Q2 2018+4.7%+1.7%+3.5%
Q1 2018-3.4%+0.7%+12.6%
Q4 2017+0.5%-1.8%+2.2%
Q3 2017+9.8%+19.7%+24.3%
Q2 2017-5.2%-3.7%-1.7%
Q1 2017+4.9%+1.0%+4.7%
Q4 2016-3.1%-2.1%+2.5%
Q3 2016-5.6%-4.9%+7.1%
Q2 2016-14.3%-11.7%-13.1%
Q1 2016-9.4%
Q4 2015+4.2%
Q3 2015+12.3%
Q2 2015+2.5%
Q1 2015+4.8%
Q4 2014-0.9%
Q3 2014+7.0%
Q2 2014-16.8%
Q1 2014+6.1%
Q4 2013+1.4%
Q3 2013+7.1%
Q2 2013+2.3%
Q1 2013+7.9%
Q1 2011+0.4%
Q4 2010+0.4%
Q4 2012+5.8%
Q3 2011-20.7%
Q3 2012-16.2%
Q4 2011-0.7%
Q2 2011-0.7%
Q2 2012+0.0%
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro